Wednesday, July 8, 2026

pharma · Lymphoma · Gastrointestinal Stromal Tumors · COGT

Cogent Biosciences

Cogent Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker COGT. Primary therapeutic focus areas include Lymphoma, Gastrointestinal Stromal Tumors, Advanced Systemic Mastocy

275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US HQ
2014 Founded
283 Employees
Public company Type
COGT · NYSE Ticker
Company details
Status
Public
HQ
275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US
Founded
2014
Employees
283
Programs
13
Drugs
8
Patents
10
Clinical program

CGT4255

Phase 1 · small molecule · Advanced Solid Tumor, Adult

CGT4255 for Advanced Solid Tumor, Adult is a Phase 1 program (small_molecule) at Cogent Biosciences with 1 ClinicalTrials.gov record(s).

← All Cogent Biosciences projects Phase 1 small molecule active

Internal code CGT4255-25-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cogent Biosciences
Phase
Phase 1
Modality
small_molecule
Indication
Advanced Solid Tumor, Adult
Status
active
Trials
1

Clinical trials